key: cord-0987626-m93cqsig authors: Guo, Zhanjun; Li, Heng-Hong; Shiao, Yih-Horng title: Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas date: 2022-03-10 journal: Front Oncol DOI: 10.3389/fonc.2022.860964 sha: 19af72635cb9b1e9e2c180fbabe589ce7cea8cd9 doc_id: 987626 cord_uid: m93cqsig nan The predictive value of the IReRS was first obtained in a randomized training set of 224 patients and subsequently validated in a test set of 142 patients or a combination of the two sets, strengthening its predictive power. Wei et al. demonstrated for the first time upregulation of FAM57A in HCCs and its associations with tumor stage/grade, immune-checkpoint activation, immune-cell infiltration, and poor survival. The upregulation was first discovered by comparing the transcriptome of over 700 HCC tumor samples with that of over 260 non-tumor samples in Gene Expression Omnibus (GEO), International Cancer Genome Consortium (ICGC), TCGA, and Cancer Cell Line Encyclopedia databases, and was further confirmed by immunohistochemical analyses of 30 pairs of HCCs and adjacent non-tumor tissues. In vitro knockdown of FAM57A reduced the HCC cell number by growth inhibition and apoptotic cell death, identifying a potential therapeutic target. Zhou et al. indicated that six immune-related lncRNAs including MSC-AS1, AC145207.5, SNHG3, AL365203.2, AL031985.3, and NRAV were upregulated at advanced grade, tumor-stage, and T-stage. They found that the increased levels of lncRNAs were significantly associated with lower overall survival, and a signature based on the risk score of the six lncRNAs was an independent prognostic factor in patients suffering from HCC. The signature of immune-related lncRNAs was also associated with immune-cell infiltration in HCC. The research showed that patients with a high signature score of immune-related lncRNAs also had a high level of immune checkpoint genes and these patients presented worse survival rates than those with a low signature score. Qi et al. used some tumor mutation burden (TMB)-associated lncRNAs to establish an eight-lncRNA prognostic signature, which was subsequently validated as a independent prognostic factors for HCC. Patients with a high score in the eight-lncRNA prognostic signature tended to possess increased immune infiltration and TMB. In addition, the finding was further confirmed in a competitive endogenous RNA (ceRNA) network named LINC00638/miR-4732-3p/ULBP1, which was newly constructed by the investigators. Zhu et al. identified LINC00485 as a potential diagnostic and prognostic biomarker for HCC. LINC00485 was selected by screening the TCGA database, and the increase of LINC00485 level was found in serum samples of HCC patients. Combination of LINC00485 with alpha fetoprotein (AFP) improved the detection rate of HCC. To explore the possible mechanisms of LINC00485 to HCC progression, a lncRNA-miRNA-mRNA regulatory network was proposed based on analysis using lncRNA and miRNA target prediction tools. In the review article entitled "Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy", the authors briefly summarized the clinical trials in the treatment of HCC using immune checkpoint inhibitors (ICI), reviewed potential predictive biomarkers for response to ICI-based treatment, and discussed potential biomarkers for ICI treatment-related adverse events. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries Intratumoural Immune Heterogeneity as a Hallmark of Tumour Evolution and Progression in Hepatocellular Carcinoma Recent Advances in Systemic Therapy for Hepatocellular Carcinoma SC2disease: A Manually Curated Database of Single-Cell Transcriptome for Human Diseases CancerSCEM: A Database of Single-Cell Expression Map Across Various Human Cancers Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The views expressed do not necessarily represent those of the US Federal agency ZG, H-HL, and Y-HS drafted and revised the manuscript. All authors contributed to the article and approved the submitted version.